$EBS

Emergent BioSolutions Inc.

Emergent BioSolutions is a global life sciences company focused on preparedness and response solutions for public health threats, including chemical, biological, radiological and nuclear threats, emerging infectious diseases, health crises, and acute and emergency care. Its products address threats such as smallpox, mpox, anthrax, Ebola and opioid overdose. Emergent’s commercial products include NARCAN® and KLOXXADO® naloxone nasal sprays. Its medical countermeasure portfolio includes vaccines and treatments such as ACAM2000®, BioThrax®, CYFENDUS®, Ebanga™ and TEMBEXA®. Emergent sells products to consumers, pharmacies, government customers and other organizations, with government procurement a primary focus for its medical countermeasures. It also provides development, drug substance and drug product manufacturing, filling and packaging services to biopharmaceutical companies and non-governmental organizations. It earns money from product sales and procurement, bioservices for external customers, and contract and grant funding for research and development. Emergent is headquartered in Gaithersburg, Maryland.

No enriched coverage for $EBS in the last 7 days.

No SEC Form 4 filings for $EBS in the last 30 days.

See all $EBS insider activity →
Med

Emergent BioSolutions Inc (EBS) (Q3 2026) Earnings Call Highlights: Revenue Timing Weighs

Emergent BioSolutions reported Q3 2026 revenue of $110M, down from $231M in Q3 2025 due to MCM delivery timing. Adjusted EBITDA was -$5M, with adjusted gross margin at 28%. Full-year 2026 revenue guidance was updated to $600M-$645M. The company faces competitive pricing pressure in the naloxone market and expects MCM revenues to decline. CFO Richard Lindahl is retiring, and net leverage remained stable at 2.4 times.

Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War

Emergent BioSolutions Inc. (EBS) filed an SEC Form 8-K — Other Events. Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax ® (Anthrax Vaccine Adsorbed) to the U.S. Department of War GAITHERSBURG, Md., Nov. 04, 2026 (BUSINESSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has received a

EBS sentiment & insider activity

Recent EBS coverage spans earnings, financial news and corporate actions.

What's driving EBS

AlphAI scores every news story that mentions EBS with an AI model for sentiment and relevance, and aggregates insider trades from Emergent BioSolutions Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $EBS

Score

Emergent BioSolutions Inc (EBS) (Q3 2026) Earnings Call Highlights: Revenue Timing Weighs

Emergent BioSolutions reported Q3 2026 revenue of $110M, down from $231M in Q3 2025 due to MCM delivery timing. Adjusted EBITDA was -$5M, with adjusted gross margin at 28%. Full-year 2026 revenue guidance was updated to $600M-$645M. The company faces competitive pricing pressure in the naloxone market and expects MCM revenues to decline. CFO Richard Lindahl is retiring, and net leverage remained stable at 2.4 times.

$EBSMedContract· supplier · $22.3M

Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War

Emergent BioSolutions Inc. (EBS) filed an SEC Form 8-K — Other Events. Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax ® (Anthrax Vaccine Adsorbed) to the U.S. Department of War GAITHERSBURG, Md., Nov. 04, 2026 (BUSINESSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has received a

Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War

Emergent BioSolutions received a $22.3 million order modification to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War. The order is part of an existing contract to provide the vaccine for military use. According to the company, this supports preparedness against biological threats like anthrax.

$EBSMedEarnings

EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

Emergent BioSolutions Inc. (EBS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS • Third Quarter 2026 Total Revenues of $110.0 million • Third Quarter 2026 Net Loss of $32.7 million and Net Loss Margin was (30)% • Third Quarter 2026 Adjusted Net Loss of $18.7 million • Third Quarter 2026 Gross

$EBSLowExec change· retired

Emergent BioSolutions Inc. (EBS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Emergent BioSolutions Inc. (EBS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl • Appointment of Frank Vargo, VP, Treasurer, to Interim CFO effective January 1, 2027 GAITHERSBURG, Md., October 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today anno

NVAX, EBS, ARCT, MRNA Rally After Russia Plague Lab Worker's Death: Retail Traders Eye 'Contract Awards'

Novavax (NVAX), Moderna (MRNA), Emergent BioSolutions (EBS), and Arcturus Therapeutics (ARCT) surged 20%, 7%, 14%, and 13% respectively, following a Russian lab worker's death. Retail investors speculated about potential government contracts. Other related stocks like Alpha Pro Tech (APT), Lakeland Industries (LAKE), and NanoViricides (NNVC) also rose. The WHO and U.S. officials downplayed the risk, but traders anticipated increased preparedness spending.

Related tickers